Teva Pharmaceutical Industries Total Liabilities 2010-2024 | TEVA

Teva Pharmaceutical Industries total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Teva Pharmaceutical Industries total liabilities for the quarter ending June 30, 2024 were $34.774B, a 1.73% decline year-over-year.
  • Teva Pharmaceutical Industries total liabilities for 2023 were $35.353B, a 0.17% decline from 2022.
  • Teva Pharmaceutical Industries total liabilities for 2022 were $35.413B, a 2.77% decline from 2021.
  • Teva Pharmaceutical Industries total liabilities for 2021 were $36.422B, a 7.98% decline from 2020.
Teva Pharmaceutical Industries Annual Total Liabilities
(Millions of US $)
2023 $35,353
2022 $35,413
2021 $36,422
2020 $39,579
2019 $42,407
2018 $44,889
2017 $51,870
2016 $58,064
2015 $24,306
2014 $23,065
2013 $24,872
2012 $27,742
2011 $27,799
2010 $16,150
2009 $14,551
Teva Pharmaceutical Industries Quarterly Total Liabilities
(Millions of US $)
2024-06-30 $34,774
2024-03-31 $35,230
2023-12-31 $35,353
2023-09-30 $34,576
2023-06-30 $35,387
2023-03-31 $34,844
2022-12-31 $35,413
2022-09-30 $34,734
2022-06-30 $36,103
2022-03-31 $36,799
2021-12-31 $36,422
2021-09-30 $36,400
2021-06-30 $37,884
2021-03-31 $38,029
2020-12-31 $39,579
2020-09-30 $39,145
2020-06-30 $40,167
2020-03-31 $40,742
2019-12-31 $42,407
2019-09-30 $42,322
2019-06-30 $44,173
2019-03-31 $44,033
2018-12-31 $44,889
2018-09-30 $45,927
2018-06-30 $47,662
2018-03-31 $49,079
2017-12-31 $51,870
2017-09-30 $55,787
2017-06-30 $56,747
2017-03-31 $55,531
2016-12-31 $58,064
2016-09-30 $61,719
2016-06-30 $25,897
2016-03-31 $24,535
2015-12-31 $24,306
2015-09-30 $25,725
2015-06-30 $27,286
2015-03-31 $24,274
2014-12-31 $23,065
2014-09-30 $22,938
2014-06-30 $23,145
2014-03-31 $23,862
2013-12-31 $24,872
2013-09-30 $25,462
2013-06-30 $25,893
2013-03-31 $25,255
2012-12-31 $27,742
2012-09-30 $26,508
2012-06-30 $25,988
2012-03-31 $27,270
2011-12-31 $27,799
2011-09-30 $18,339
2011-06-30 $16,409
2011-03-31 $16,120
2010-12-31 $16,150
2010-09-30 $17,330
2010-06-30 $15,822
2010-03-31 $14,368
2009-12-31 $14,551
2009-09-30 $13,994
2009-06-30 $14,401
2009-03-31 $16,106
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00